Cargando…
Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial–Mesenchymal Transition
Maximum tolerable dosing (MTD) of chemotherapeutics has long been the gold standard for aggressive malignancies. Recently, alternative dosing strategies have gained traction for their improved toxicity profiles and unique mechanisms of action, such as inhibition of angiogenesis and stimulation of im...
Autores principales: | Davis, Joshua T., Ghosh, Taraswi Mitra, Mazumder, Suman, Mitra, Amit, Bird, Richard Curtis, Arnold, Robert D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218056/ https://www.ncbi.nlm.nih.gov/pubmed/37239838 http://dx.doi.org/10.3390/ijms24108490 |
Ejemplares similares
-
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2023) -
Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2021) -
Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer
por: Mazumder, Suman, et al.
Publicado: (2022) -
Adverse drug reaction after intravitreal injection of topotecan
por: Narang, Subina, et al.
Publicado: (2020) -
Clinical significance of epithelial-mesenchymal transition
por: Steinestel, Konrad, et al.
Publicado: (2014)